Corcept Therapeutics Inc

CORT

Equity

ISIN null / Valor 1812837

NASDAQ (2026-06-02)

USD 71.20+1.08%

Corcept Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Corcept Therapeutics Inc. is a biopharmaceutical company focused on therapies that modulate the glucocorticoid receptor to treat diseases driven by excess cortisol signaling; it commercializes Korlym (mifepristone) in the United States for control of hyperglycemia in patients with endogenous Cushing’s syndrome who are not candidates for surgery and generates revenue from product sales while advancing a pipeline of selective glucocorticoid receptor modulators, most notably relacorilant, which is being evaluated in Cushing’s and in combination regimens for certain solid tumors. The company’s operations combine clinical development, regulatory work and commercial activities to pursue additional indications for its marketed product and to progress investigational GR-targeting candidates, and it is publicly traded on NASDAQ under the ticker CORT.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue — Q4 and Full Year

Q4 2025 product revenue: $202.125 million (vs. $181.890M in Q4 2024). Full‑year 2025 product revenue: $761.407 million, up from $675.040 million in 2024.

Profitability — Q4 and Full Year

Q4 2025 net income: $24.288 million. Full‑year 2025 net income: $99.652 million (down from $141.209M in 2024). Operating income and margins were pressured by higher operating expenses in 2025.

Expenses and Margins

Total operating expenses for 2025 rose to $716.61 million from $538.09 million in 2024, driven mainly by higher selling, general & administrative (SG&A) and continued R&D spending, which reduced operating income to $44.797 million for the year.

Cash, Balance Sheet and Liquidity

Cash and investments at December 31, 2025 were $532.4 million. Total assets were $836.7 million and stockholders’ equity was $647.8 million.

Earnings per Share

Q4 2025 basic net income per common share: $0.23; diluted: $0.20. Full‑year 2025 basic EPS: $0.95; diluted EPS: $0.82.

2026 Guidance

Management provided 2026 revenue guidance of $900–$1,000 million, reflecting expected recovery and continued expansion of the Cushing’s franchise after resolving specialty‑pharmacy constraints.

Commercial/Operational Update

Company reported record new prescriptions and new prescribers in 2025 and a 37% increase in tablets sold versus prior year, but growth was constrained by prior specialty‑pharmacy capacity; the transition to a new specialty pharmacy is complete and February (2026) was indicated to be on track as a record month for new patients starting treatment.

Regulatory and Pipeline Items Relevant to Outlook

Corcept highlighted key regulatory and clinical milestones that could affect future revenue: an FDA review pathway engagement for relacorilant in Cushing’s syndrome, a July 11, 2026 PDUFA date for relacorilant plus nab‑paclitaxel in platinum‑resistant ovarian cancer, and ongoing Phase 2/3 programs (ROSELLA, BELLA, MONARCH, DAZALS) with several near‑term readouts and trial starts noted.

Summarized from source with an LLMView Source

Key figures

-0.67%1Y

206%3Y

233%5Y

Performance

91.1%1Y

82.2%3Y

69.3%5Y

Volatility